Health & Safety Industry Today
Fractional Flow Reserve–Computed Tomography (FFR-CT) Market will reach $1.4 Billion by 2033- Strategic Revenue Insights
London, UK – November 2025 | Strategic Revenue Insights Inc. – The global Fractional Flow Reserve–Computed Tomography (FFR-CT) Market is projected to climb from about USD 52.2 million in 2024 to nearly USD 1.4 billion by 2033, according to the latest research by Strategic Revenue Insights. That jump corresponds to a compound annual growth rate (CAGR) of 12.5%, as demand mounts for non-invasive cardiac diagnostic tools in cardiovascular care.
The current market size reflects a nascent but rapidly expanding segment: FFR-CT is increasingly recognized as a transformative diagnostic technique in cardiology, blending coronary CT angiography with computational fluid dynamics to assess pressure drops in coronary arteries without the need for invasive catheterization. Its projected rise to USD 1.5 billion by 2033 underscores the strength of its clinical case and the momentum behind non-invasive diagnostics.
Several factors are fueling this surge. First, cardiovascular disease especially coronary artery disease (CAD) remains a leading health burden worldwide, pushing clinicians and healthcare systems to adopt safer, patient-friendly diagnostics. Strategic Revenue Insights’ report highlights that growing clinical confidence in FFR-CT algorithms and improved data-processing software is helping hospitals make more informed decisions before resorting to invasive tests. Meanwhile, advancements in imaging technologies including more efficient CT scanners and AI-driven image reconstruction are driving both accuracy and throughput. On top of that, favorable policy and reimbursement shifts in key markets are helping FFR-CT move from research settings into standard care pathways. These growth drivers combine to give the FFR-CT market a powerful tailwind.
Regionally, North America leads the way, thanks to sophisticated healthcare infrastructure, early adoption of advanced imaging, and supportive reimbursement schemes. Europe follows closely, where clinical guidelines increasingly recognize physiological diagnostics as essential in CAD management. But perhaps the most compelling story lies in Asia-Pacific: growing healthcare investments, rising CAD incidence, and accelerating adoption of non-invasive diagnostics are positioning the region as a high-growth frontier for FFR-CT. Emerging markets in Latin America and the Middle East are also expected to contribute meaningfully as diagnostic centers expand and digital health solutions scale.
Strategic Revenue Insights segments the FFR-CT market across several dimensions. From a technology standpoint, the report divides it into algorithmic components (software), imaging techniques (CT hardware), and data processing tools, acknowledging the synergy needed between hardware and software to deliver precise results. In terms of applications, cardiology dominates due to FFR-CT’s direct relevance in diagnosing CAD, but there is growing use in radiology and surgical planning, particularly when pre-intervention lesion assessment is required. End-users span hospitals, diagnostic imaging centers, and research institutions, each leveraging FFR-CT in their own way hospitals for routine care, imaging centers for non-invasive screening, and research institutes for developing next-gen algorithms.
On the competitive front, Strategic Revenue Insights identifies Siemens Healthineers, Philips, GE Healthcare, Abbott Laboratories, Medtronic, Terumo, Boston Scientific, Bracco SpA, and HeartFlow as leading players. These companies are pushing the technology forward through integrated CT-software offerings, cloud-based analytics, and partnerships, thereby deepening FFR-CT’s clinical reach.
Looking ahead, the future of the FFR-CT market appears very bright. As algorithm sophistication and computational speed improve, we anticipate even broader adoption in routine cardiology workflows. Hospitals will increasingly rely on FFR-CT for pre-treatment triage, reducing unnecessary invasive angiographies and optimizing patient management. There’s strong potential for FFR-CT to play a bigger role in preventive cardiology too by identifying hemodynamically significant lesions before they become clinically critical. At the same time, emerging economies will likely drive a new wave of uptake as healthcare infrastructure modernizes and diagnostic centers proliferate. For investors, device makers, and healthcare providers alike, the coming decade promises both innovation and scale in a market once confined to academic and specialized settings.
Browse the associated report
About Strategic Revenue Insights Inc.
Strategic Revenue Insights Inc., a subsidiary of SRI Consulting Group Ltd, empowers organizations worldwide with data-driven market intelligence. Headquartered in London, United Kingdom, we deliver syndicated research reports, tailored consulting solutions, and actionable insights that equip clients to make confident, future-focused strategic decisions. Our team of seasoned analysts based in London and connected globally continuously tracks markets, identifies emerging trends, and uncovers growth opportunities to support long-term client success. As part of SRI Consulting Group Ltd, we are committed to accuracy, clarity, and practical relevance, helping businesses navigate competitive sectors, optimize strategies, and accelerate revenue growth.
Media Contact
Company Name: Strategic Revenue Insights Inc.
Contact Person: Ashwani
Email: sales@strategicrevenueinsights.com
Phone: +44 7877403352
Address: Suite 10, Capital House, 61 Amhurst Road, E8 1LL
City: London
Country: United Kingdom
Website: www.strategicrevenueinsights.com
Share on Social Media
Contact Information
Rohit Bhisey
Strategic Revenue Insights Inc.
Suite10 Capital House 61 Amhurst Road,
London
London
United kingdom
E8 1LL
07877403352
https://www.strategicrevenueinsights.com/
Other Industry News
Ready to start publishing
Sign Up today!
